Table 5

HMG-CoA reductase activity in hamster hepatic microsomes (pmol [14C]mevalonolactone/min/mg microsomal protein)

Group

Activity-NaF

Total activity+NaF


Control

12.36

9.30

Lovastatin

13.34

ND

Gl (2.5%)

5.86a

2.66a

Gl (5%)

8.08a

4.86a


Refer to the text for methodologic details. [14C]mevalonate was converted to [14C]mevalonolactone with 10 M HCl before the TLC step. Values above were corrected for recovery (15–63%) with [3H]mevalonate. G. lucidum, but not lovastatin, was found to inhibit ex vivo synthesis whether: recovery was accounted for; results were expressed per gram liver weight; [14C]mevalonolactone was first extracted into organic solvent and then applied to TLC plates [79] rather than applying aqueous extracts directly to TLC plates [55] as reported above (data not shown); and whether or not endogenous phosphatase activity was inhibited with 50 mM NaF (shown above). Values represent mean of 6 determinations. aSignificantly different from control, students unpaired, 2-tailed t-test, equal variances (P < 0.05). ND, not determined.

Berger et al. Lipids in Health and Disease 2004 3:2   doi:10.1186/1476-511X-3-2

Open Data